Gibson Dunn has advised Denali Therapeutics. Goodwin Procter and Maiwald have advised Royalty Pharma. Denali Therapeutics Inc. (Nasdaq: DNL) and Royalty Pharma plc (Nasdaq: RPRX) have...
Denali Therapeutics Enters $275 Million Synthetic Royalty Funding Agreement with Royalty Pharma
Ultragenyx Sells Portion of Future Crysvita Royalties to OMERS for $400 Million
Gibson, Dunn & Crutcher LLP has advised Ultragenyx Pharmaceutical Inc. Davies Ward Phillips & Vineberg LLP, Latham & Watkins LLP, and Sidley Austin LLP have advised...
Technip Energies Acquires Ecovyst’s Advanced Materials & Catalysts Business for $556 Million
Gibson Dunn has advised Technip Energies on the deal, and Ropes & Gray has advised Ecovyst Inc. Technip Energies has entered into a definitive agreement to...
Constellation Wealth Capital Acquires Minority Stake in Merit Financial Advisors
Gibson, Dunn & Crutcher has advised Constellation Wealth Capital on the deal. Holland & Knight and Kirkland & Ellis have advised Merit Financial Advisors. Constellation Wealth...
Sammons Financial Group to Acquire Wealthcare
Berkshire Global Advisors and Gibson, Dunn & Crutcher LLP have advised Sammons Financial Group, while Republic Capital Group and Blank Rome LLP have represented Wealthcare and...
AIP Management’s Investment in Silicon Ranch Corporation
Gibson Dunn & Crutcher is advising AIP Management on the transaction. AIP Management (“AIP”) announced its agreement to invest in Silicon Ranch Corporation, one of the...
Veritas Capital’s $3.1 Billion Acquisition of Wood Mackenzie
Gibson, Dunn & Crutcher advised Veritas, while Davis Polk advised Verisk on the deal. Verisk announced the sale of its energy business, Wood Mackenzie, to an...